• Leviathan Natural Products (EPIC) has sold its 100-per-cent interest in Woodstock Biomed Inc. for $5,000,000
  • Proceeds from the sale will be used for general corporate purposes and working capital needs
  • Woodstock Biomed Inc. operates as a pharmaceutical company with a special focus on the production of medical cannabis for clients across Canada
  • In addition, the board of directors of Leviathan has appointed Linda Marabeti Romano as chief financial officer
  • Leviathan Natural Products Inc. is a multi-dimensional cannabis company focused on its retail customers and technology to democratize cannabis markets
  • Leviathan Natural Products Inc. opened trading at $1.24 per share

Leviathan Natural Products (EPIC) has sold its 100-per-cent interest in Woodstock Biomed Inc. for $5,000,000.

Proceeds from the sale will be used for general corporate purposes and working capital needs.

Woodstock Biomed Inc. operates as a pharmaceutical company with a special focus on the production of medical cannabis for clients who use marijuana for medical treatments across Canada.

Woodstock Biomed owns a 30-acre property with greenhouse infrastructure in Pelham, Ontario, from where it produces its cannabis, mainly supplied to pharmaceuticals and horticulturalists.

In addition, the board of directors of Leviathan has appointed Linda Marabeti Romano as chief financial officer.

Marabeti Romano replaces Manish Z. Kshatriya effective immediately.

Linda Marabeti Romano brings 20 years of work experience in corporate accounting, finance, tax, audit and assurance.

Leviathan Natural Products Inc. is a multi-dimensional cannabis company focused on its retail customers and technology to democratize cannabis markets.

Leviathan Natural Products Inc. opened trading at $1.24 per share.


More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.